Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Menée à partir de données portant sur 1 344 patients atteints d'un cancer de stade avancé traité par nivolumab et/ou ipilimumab, cette étude met en évidence une association entre un niveau sérique élevé d'interleukine IL-8, l'augmentation de la concentration intratumorale de neutrophiles et une réduction de l'efficacité des inhibiteurs de point de contrôle immunitaire
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.
Nature Medicine , résumé, 2020